Drug intelligence / Profile preview

VV913

Development stage: Phase 2
Lead developer: Vigonvita Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

VV913 is a novel small-molecule drug candidate being developed by Vigonvita Life Sciences for the treatment of premature ejaculation (PE). Characterized by a unique chemical structure, VV913 is designed to provide a therapeutic option with superior efficacy and an improved safety profile compared to existing treatments. Preclinical studies in rat models of premature ejaculation have demonstrated significant efficacy following a single administration. The compound is currently undergoing Phase I clinical trials in China, which are evaluating the safety, tolerability, and pharmacokinetics of single ascending oral doses in healthy male participants.

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on VV913.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VV913.

Explore the full profile